Ono Venture Investment, Inc.

Ono Venture Investment, Inc. (OVI) is the corporate venture capital arm of Ono Pharmaceutical Co., Ltd., an R&D-oriented pharmaceutical company known for delivering 'First in class' medicines such as OPDIVO® (nivolumab). OVI was established in May 2020 to accelerate open innovation by investing in bio-venture companies and startups that offer novel drug discovery targets and cutting-edge technologies. The firm aims to access and partner on drug discovery targets and advanced technologies to generate innovative medicines.

OVI's investment strategy focuses on early-stage biotechnology companies, particularly those in the seed to Series B stages. The firm has a geographical focus on the United States and Japan, aligning with its parent company's global presence. OVI's portfolio includes investments in various sectors within the biotechnology and pharmaceutical industries, reflecting its commitment to advancing healthcare through strategic partnerships.

Since its inception, OVI has expanded its investment pool to support its mission. In December 2023, Ono Pharmaceutical Co., Ltd. increased its investment in OVI FI to US$200 million, doubling the previous amount to accelerate open innovation and make strategic investments in bio-venture companies. This expansion underscores OVI's dedication to fostering innovation and achieving sustainable growth through the creation of innovative new drugs.